Vincerx Pharma Inc (VINC)
0.659
-0.02
(-3.63%)
USD |
NASDAQ |
May 28, 16:00
0.6584
0.00 (0.00%)
After-Hours: 05:16
Vincerx Pharma Enterprise Value: 14.35M for May 28, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 28, 2024 | 14.35M |
| May 24, 2024 | 15.09M |
| May 23, 2024 | 15.67M |
| May 22, 2024 | 15.56M |
| May 21, 2024 | 16.14M |
| May 20, 2024 | 15.04M |
| May 17, 2024 | 15.29M |
| May 16, 2024 | 16.15M |
| May 15, 2024 | 16.98M |
| May 14, 2024 | 17.47M |
| May 13, 2024 | 17.34M |
| May 10, 2024 | 18.59M |
| May 09, 2024 | 19.99M |
| May 08, 2024 | 19.40M |
| May 07, 2024 | 19.03M |
| May 06, 2024 | 19.82M |
| May 03, 2024 | 20.79M |
| May 02, 2024 | 22.36M |
| May 01, 2024 | 21.15M |
| April 30, 2024 | 19.31M |
| April 29, 2024 | 14.66M |
| April 26, 2024 | 12.07M |
| April 25, 2024 | 15.99M |
| April 24, 2024 | 16.78M |
| April 23, 2024 | 17.25M |
| Date | Value |
|---|---|
| April 22, 2024 | 15.34M |
| April 19, 2024 | 14.89M |
| April 18, 2024 | 16.07M |
| April 17, 2024 | 17.25M |
| April 16, 2024 | 17.01M |
| April 15, 2024 | 15.36M |
| April 12, 2024 | 17.95M |
| April 11, 2024 | 16.30M |
| April 10, 2024 | 16.30M |
| April 09, 2024 | 17.59M |
| April 08, 2024 | 97.25M |
| April 05, 2024 | 113.73M |
| April 04, 2024 | 121.66M |
| April 03, 2024 | 136.22M |
| April 02, 2024 | 131.29M |
| April 01, 2024 | 120.16M |
| March 28, 2024 | 95.57M |
| March 27, 2024 | 116.98M |
| March 26, 2024 | 96.85M |
| March 25, 2024 | 93.40M |
| March 22, 2024 | 94.68M |
| March 21, 2024 | 103.89M |
| March 20, 2024 | 130.65M |
| March 19, 2024 | 122.09M |
| March 18, 2024 | 92.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-69.32M
Minimum
Jun 16 2022
300.40M
Maximum
Mar 16 2021
46.71M
Average
-0.37M
Median
Enterprise Value Benchmarks
| Trxade Health Inc | 14.70M |
| MyMD Pharmaceuticals Inc | 3.048M |
| Acrivon Therapeutics Inc | 128.39M |
| Ligand Pharmaceuticals Inc | 1.234B |
| Regulus Therapeutics Inc | 37.20M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.43M |
| Total Expenses (Quarterly) | 7.478M |
| EPS Diluted (Quarterly) | -0.58 |
| Earnings Yield | -271.6% |